Health

  • October 27, 2025

    Bros. Had No Fraud Intent In HIV Drug Scam, Fla. Jury Told

    Two Maryland brothers accused of orchestrating a roughly $100 million misbranded HIV drug scheme told a Florida federal jury Monday they had no intent to defraud, saying they were deceived by a co-conspirator who they made a partner in their company. 

  • October 27, 2025

    CFPB Says States Can't Enact Medical Debt Reporting Bans

    The Consumer Financial Protection Bureau said Monday that it now believes federal law blocks efforts by states to ban medical debt from credit reports or enact most other credit reporting rules of their own, breaking sharply from its Biden-era stance on the topic.

  • October 27, 2025

    CVS Let 401(k) Get Bogged Down With High Fees, Suit Says

    CVS costs workers millions in retirement savings and violated federal benefits law by failing to rein in excessive administrative fees in its $27 billion 401(k) plan, a former pharmacist said in a proposed class action filed in New York federal court.

  • October 27, 2025

    Acadia Pushes For Appeal Of Investors' Partial Early Win

    Acadia Healthcare Company Inc. is looking to appeal a partial early win granted to a proposed class of investors accusing the company of misleading them about the strength of its United Kingdom operations, arguing that the court's recent ruling presents controlling questions of law warranting immediate appellate review.

  • October 27, 2025

    LifeScan Gets Final OK On Ch. 11 Plan After Deal With PBMs

    A Texas bankruptcy judge on Monday granted confirmation of LifeScan Global Corp.'s Chapter 11 plan after the debtor reached an agreement with pharmacy benefit managers that resolved their objections, allowing the glucose-monitor maker to complete a deal to cut about $1.4 billion of debt.

  • October 27, 2025

    Feds Fight Union Bid To Protect Jobs During Gov't Shutdown

    The Trump administration is fighting a group of unions' request for a California federal judge to block the government from laying off federal workers during the shutdown, saying the injunction request from eight unions is far too broad.

  • October 27, 2025

    AbbVie Defends Challenge Of Colorado's Discount Drug Law

    AbbVie defended its lawsuit challenging a Colorado law it says conflicts with federal law by forcing manufacturers to sell drugs at steep discounts to Walgreens, CVS and other pharmacy chains, telling a federal judge that the state compels the biotech company to sell more discounted drugs than federal law requires.

  • October 27, 2025

    Temp Agency Placed Unqualified Nursing Aides, Charges Say

    A Massachusetts temporary staffing agency sent unqualified nursing aides into at least four healthcare facilities by misrepresenting their credentials, and it allowed one of them to use the identity of a former employee, the state's attorney general alleged in an indictment announced Monday.

  • October 27, 2025

    Colo. Doctor Sues Ex-Employer For Disability Discrimination

    A Colorado emergency physician has filed a discrimination lawsuit against his former employer, alleging the healthcare provider terminated him because of his disability and accommodation requests.

  • October 27, 2025

    Pa. Hospital Workers Seek Initial Approval For OT Suit Deal

    A health system agreed to a $70,000 deal to end a proposed class action alleging it failed to pay unionized hospital workers proper overtime wages, according to an unopposed motion for preliminary approval that the workers filed in Pennsylvania federal court Friday.

  • October 27, 2025

    Judge Tosses Eli Lilly Suit Over Telehealth Weight Loss Drugs

    A California federal court has dismissed a lawsuit from Eli Lilly against a telehealth company and related entities over the compounding of its popular weight loss drugs Mounjaro and Zepbound, saying the pharmaceutical giant's complaint failed to plausibly allege claims under the Lanham Act and the state's false advertising and consumer protection laws.

  • October 27, 2025

    Biotech Firm MapLight Inks $251M IPO Amid Shutdown

    Biotechnology company MapLight Therapeutics began trading publicly Monday after raising $251 million in its initial public offering, which marked a rare listing during the ongoing federal government shutdown.

  • October 27, 2025

    Ex-Magellan CEO Avoids Prison Over Faulty Lead Tests

    The former CEO of Magellan Diagnostics was sentenced in Massachusetts federal court Monday to a year of home confinement for failing to alert regulators to a problem in the company's lead-testing devices that resulted in inaccurately low lead levels being detected in blood samples.

  • October 24, 2025

    Gordon Rees 'Profoundly Embarrassed' By Atty's AI Mistakes

    Gordon Rees Scully Mansukhani LLC has apologized to an Alabama bankruptcy court for a filing submitted by one of its lawyers that contained mistakes it blamed on artificial intelligence, saying it's "profoundly embarrassed" by the incident and will accept whatever sanctions end up being issued.

  • October 24, 2025

    Calif. Dialysis Bill Violates Free Speech, 9th Circ. Told

    Attorneys for healthcare providers, dialysis patients and a charity urged the Ninth Circuit in a Friday hearing to reverse a district court ruling upholding part of a California law capping profits for dialysis providers that donate to a charitable fund that then supports insurance payments for the providers' patients.

  • October 24, 2025

    Curaleaf Urges Block On NJ Pot Shop Union Rule

    Curaleaf asked a New Jersey federal judge Friday to block state cannabis industry regulators from making cannabis retailers sign labor peace agreements with unions, saying the requirement treads on the retailers' rights under the National Labor Relations Act.

  • October 24, 2025

    Pfizer Hit With More Suits Over Depo-Provera

    Three women sued Pfizer this week in Florida federal court, alleging its hormonal contraceptive birth control shot Depo-Provera caused their brain tumors in the latest claims that the major drugmaker failed to warn of the link.

  • October 24, 2025

    USAA Defends Medical Reimbursement Cuts In Coverage Row

    Two USAA units sought to toss two insureds' proposed class action accusing the companies of under-reimbursing their medical providers via claim handling software, telling a Washington federal court "there is no admissible evidence that plaintiffs' treatments were medically necessary and related to their auto accidents."

  • October 24, 2025

    2 Texas Justices Say Qui Tam Constitutionality Needs Review

    The Texas Supreme Court has rejected a bid from Novartis Pharmaceuticals Corp. to examine the constitutionality of state law-based qui tam claims, but on Friday two justices submitted a statement saying the court will have to address the issue eventually.

  • October 24, 2025

    3rd Circ. Revives Nonprofit's Bias Suit Over Permit Denial

    The Third Circuit on Friday revived an alcohol and substance abuse recovery nonprofit's disability bias suit against a New Jersey town, reasoning that the district court improperly denied the plaintiff the opportunity to refine its allegations that the municipality denied it a permit based on the nature of its operation.

  • October 24, 2025

    Mich. Patients, Doctors Fight Pregnancy End-Of-Life Carveout

    A group of Michigan couples and doctors has sued to challenge a Michigan law that prevents medical professionals and family members from honoring the end-of-life medical care decisions of pregnant women who refuse life-sustaining care.

  • October 24, 2025

    LifeScan Urges Court To Force PBMs To Produce Documents

    Glucose monitor maker LifeScan has asked a Texas bankruptcy judge to force pharmacy benefit managers to produce documents amid a dispute over administrative expense claims in the Chapter 11 case, saying PBMs including OptumRx and Caremark are using delay as "sword and shield."

  • October 24, 2025

    Hagens Berman Wants Judge DQ, Alleges Drug Lawsuit Bias

    Hagens Berman Sobol Shapiro LLP asserted Friday that the Pennsylvania federal judge overseeing the long-running thalidomide birth-defect litigation in the state should be recused, alleging over 100 undisclosed private contacts between the court and special discovery master as an indication of bias.

  • October 24, 2025

    NFL Players' Race Bias Claims Tossed In Concussion Case

    A Pennsylvania federal judge on Friday denied a motion by a group of 16 former football players who claimed that they were wrongly denied benefits under the National Football League's 2015 concussion injury settlement.

  • October 24, 2025

    Generic-Drug Makers Want Conn. Price Cap Blocked During Suit

    A trade group for generic and biosimilar drugmakers is asking a Connecticut federal judge to block the state's new drug price cap during the pendency of its challenge, saying it illegally controls prices on sales made outside the state.

Expert Analysis

  • How The Healthline Privacy Settlement Redefines Ad Tech Use

    Author Photo

    The Healthline settlement is the first time California has drawn a clear line in the sand around how website tracking must function in practice, so if your site uses tracking technologies, especially around sensitive content like health or finance, regulators are inspecting your website's back end, not just its banner, say attorneys at Baker Donelson.

  • How Sweeping Budget Bill Shakes Up Health Industry

    Author Photo

    With the recently passed One Big Beautiful Bill Act marking one of the most significant overhauls of federal health policy since the passage of the Affordable Care Act, providers, managed care organizations and life sciences companies must now shift focus from policy review to implementation planning, say advisers at Holland & Knight.

  • Series

    Adapting To Private Practice: From ATF Director To BigLaw

    Author Photo

    As a two-time boomerang partner, returning to BigLaw after stints as a U.S. attorney and the director of the Bureau of Alcohol, Tobacco, Firearms and Explosives, people ask me how I know when to move on, but there’s no single answer — just clearly set your priorities, says Steven Dettelbach at BakerHostetler.

  • New DOJ Penalty Policy Could Spell Trouble For Cos.

    Author Photo

    In light of the U.S. Department of Justice’s recently published guidance making victim relief a core condition of coordinated resolution crediting, companies facing parallel investigations must carefully calibrate their negotiation strategies to minimize the risk of duplicative penalties, say attorneys at Debevoise.

  • A Look At Key 5th Circ. White Collar Rulings So Far This Year

    Author Photo

    In the first half of 2025, the Fifth Circuit has decided numerous cases of particular import to white collar practitioners, which collectively underscore the critical importance of meticulous recordbuilding, procedural compliance and strategic litigation choices at every stage of a case, says Joe Magliolo at Jackson Walker.

  • High Court Cert Spotlights Varying Tests For Federal Removal

    Author Photo

    A recent decision by the U.S. Supreme Court to review Chevron v. Plaquemines Parish, a case involving the federal officer removal statute, highlights three other recent circuit court decisions raising federal removal questions, and serves as a reminder that defendants are the masters of removal actions, says Varun Aery at Hollingsworth.

  • Series

    Playing Baseball Makes Me A Better Lawyer

    Author Photo

    Playing baseball in college, and now Wiffle ball in a local league, has taught me that teamwork, mental endurance and emotional intelligence are not only important to success in the sport, but also to success as a trial attorney, says Kevan Dorsey at Swift Currie.

  • What US Medicine Onshoring Means For Indian Life Sciences

    Author Photo

    Despite the Trump administration's latest moves to onshore essential medicine manufacturing, India will likely remain an indispensable component of the U.S. drug supply chain, but Indian manufacturers should prepare for stricter compliance checks, says Jashaswi Ghosh at Holon Law Partners.

  • How US Cos. Should Prep For Brazil's Int'l Data Transfer Rules

    Author Photo

    Brazil's National Data Protection Authority's new rules concerning the processing and storing of Brazilians' personal data carry significant reputational risks for the e-commerce, financial services, education and health sectors, so U.S. companies with business in Brazil should prepare ahead of the Aug. 23 compliance date, says Juliane Chaves Ferreira at Guimarães & Vieira de Mello.

  • APA Relief May Blunt Justices' Universal Injunction Ruling

    Author Photo

    The Administrative Procedure Act’s avenue for universal preliminary relief seems to hold the most promise for neutralizing the U.S. Supreme Court’s decision in Trump v. CASA to limit federal district courts' nationally applicable orders, say attorneys at Crowell.

  • Series

    Law School's Missed Lessons: Skillful Persuasion

    Author Photo

    In many ways, law school teaches us how to argue, but when the ultimate goal is to get your client what they want, being persuasive through preparation and humility is the more likely key to success, says Michael Friedland at Friedland Cianfrani.

  • A Look At Trump 2.0 Antitrust Enforcement So Far

    Author Photo

    The first six months of President Donald Trump's second administration were marked by aggressive antitrust enforcement tempered by traditional structural remedies for mergers, but other unprecedented actions, like the firing of Federal Trade Commission Democrats, will likely stoke heated discussion ahead, says Richard Dagen at Axinn.

  • FCA Working Group Reboot Signals EHR Compliance Risk

    Author Photo

    The revival of the False Claims Act working group is an aggressive expansion of enforcement efforts by the Justice Department and the U.S. Department of Health and Human Services targeted toward technology-enabled fraud involving electronic health records and other data, say attorneys at ArentFox Schiff.

  • Litigation Inspiration: How To Respond After A Loss

    Author Photo

    Every litigator loses a case now and then, and the sting of that loss can become a medicine that strengthens or a poison that corrodes, depending on how the attorney responds, says Bennett Rawicki at Hilgers Graben.

  • FDA's Hasty Policymaking Approach Faces APA Challenges

    Author Photo

    Though the U.S. Food and Drug Administration has abandoned its usual notice-and-comment process for implementing new regulatory initiatives, two recent district court decisions make clear that these programs are still susceptible to Administrative Procedure Act challenges, says Rachel Turow at Skadden.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.